舌下含服和皮下注射特异性免疫治疗变应性鼻炎的疗效研究

尤少华; 秦晓燕; 徐丛; 邱昕; 栾兆磊; 贾红霞; 王洪田

doi:10.13201/j.issn.1001-1781.2016.09.005

舌下含服和皮下注射特异性免疫治疗变应性鼻炎的疗效研究

- 1. 解放军总医院耳鼻咽喉头颈外科(北京, 100853);
- 2. 解放军总医院临床检验科;
- 3. 解放军总医院海南分院耳鼻咽喉头颈外科

详细信息

通讯作者: 王洪田,E-mail:wht301@263.net

中图分类号: R765.21

收稿日期: 2016-01-25

Comparison study of subcutaneous immunotherapy and sublingual immunotherapy in patients with allergic rhinitis

- 1. Department of Otolaryngology-Head and Neck Surgery, Chinese PLA General Hospital, Beijing, 100853, China;
- 2. Clinical Laboratory, Chinese PLA General Hospital;
- 3. Department of Otolaryngology-Head and Neck Surgery, Hainan Branch of Chinese PLA General Hospital

More Information

Corresponding author: WANG Hongtian, E-mail: wht301@263.net

Received Date: 25 January 2016

摘要

摘要: 目的：研究舌下免疫治疗（SLIT）和皮下免疫治疗（SCIT）变应性鼻炎（AR）的依从性、疗效和安全性。方法：将115例行尘螨脱敏治疗的中-重度持续性AR患者分为SLIT组（64例）和SCIT组（51例）。记录患者的依从情况、治疗前和治疗2年时的症状评分、生活质量评分、药物评分及治疗过程中出现的不良反应。用SPSS 19.0软件对数据进行统计学分析。结果：SLIT组64例患者中40例完成了2年的SLIT，依从率为62.50%；SCIT组51例患者中43例完成了2年的SCIT，依从率为84.31%；2组的依从率差异有统计学意义（P<0.05）。接受SLIT和SCIT 2年后，患者的各项症状、生活质量和用药情况较治疗前均有显著改善（均P<0.05），但2组之间差异无统计学意义（P>0.05）。接受SLIT 2年的40例患者，未出现中重度不良反应；接受SCIT 2年的43例患者，发生了6次中重度不良反应。结论：SLIT与SCIT的疗效相当，SLIT的依从率较低，但安全性明显高于SCIT。
- 鼻炎,变应性 /
- 舌下免疫治疗 /
- 皮下免疫治疗 /
- 症状评分 /
- 生活质量评分 /
- 药物评分 /
- 依从性 /
- 不良反应
Abstract: Objective: To observe the compliance, efficacy and safety of subcutaneous immunotherapy(SLIT) and sublingual immunotherapy(SCIT) in patients with allergic rhinitis(AR).Method: One hundred and fifteen patients sensitized to house dust mites were recruited in this study. The standardized extract of house dust mites was used for SLIT in 64 cases, and the standardized extract of dual house dust mites was used for SCIT in the other 51 cases. The compliance, nasal symptom scores, the medication scores, the quality of life and the adverse reaction were evaluated before and 2 years after immunotherapy. SPSS 19.0 was used for data analysis.Result: Forty patients out of 64 completed the 2 years-SLIT, and the compliance rate was 62.50%. Forty three patients out of 51 completed the 2 years-SCIT and the compliance rate was 84.31%.The compliance rate of SLIT was significantly lower than that of SCIT(P<0.05). The nasal symptom scores, the anti-allergic medication, the scores in quality of life decreased significantly after receiving SLIT or SCIT for 2 years(P<0.05). However, the changed values of scores between the two groups had no significant differences(P>0.05). There was no moderate or severe adverse reactions occurred in SLIT group but a total of 6 moderate or severe adverse reactions occurred in SCIT group.Conclusion: SLIT has same effect compared with SCIT with a lower compliance rate but a significantly higher safety.
- rhinitis, allergic /
- sublingual immunotherapy /
- subcutaneous immunotherapy /
- symptom scores /
- quality of life /
- medication scores /
- compliance /
- adverse reactions

HTML全文

参考文献(19)

[1]	VADLAMUDI A,SHAKER M.New developments in allergen immunotherapy[J].Curr Opin Pediatr,2015,27:649-655.
[2]	DIDIER A,CAMPO P,MORENO F,et al.Dose-dependent immunological responses after a 6-month course of sublingual house dust mite immunotherapy in patients with allergic rhinitis[J].Int Arch Allergy Immunol,2016,168:182-192.
[3]	中华耳鼻咽喉头颈外科杂志编委会鼻科组,中华医学会耳鼻咽喉头颈外科学会鼻科学组.变应性鼻炎诊断与治疗指南(2009年,武夷山)[J].中华耳鼻咽喉头颈外科杂志,2009,44(12):977-978.
[4]	LIN Z,LIU Q,LI T,et al.The effects of house dust mite sublingual immunotherapy in patients with allergic rhinitis according to duration[J].Int Forum Allergy Rhinol,2016,6:82-87.
[5]	DI BONA D,PLAIA A,LETO-BARONE M S,et al.Efficacy of grass pollen allergen sublingual immunotherapy tablets for seasonal allergic rhinoconjunctivitis:a systematic review and meta-analysis[J].JAMA Intern Med,2015,175:1301-1309.
[6]	SENNA G,RIDOLO E,CALDERON M,et al.Evidence of adherence to allergen-specific immunotherapy[J].Curr Opin Allergy Clin Immunol,2009,9:544-548.
[7]	INCORVAIA C,MAURO M,RIDOLO E,et al.Sublingual immunotherapy for allergic rhinitis:where are we now[J]?Immunotherapy,2015,[Epub ahead of print]
[8]	KOBERLEIN J,KOTHE A C,SIEBER J,et al.Determining factors of patient compliance to treatment in allergic rhinitis[J].Asian Pac J Allergy Immunol,2013,31:148-156.
[9]	桂晓钟,陈涌,赵军,等.变应性鼻炎皮下注射和舌下含服特异性免疫治疗依从性对比[J].中国耳鼻咽喉头颈外科,2011,17(12):631-633.
[10]	RADULOVIC S,CALDERON M A,WILSON D,et al.Sublingual immunotherapy for allergic rhinitis[J].Cochrane Database Syst Rev,2010,12:CD002893.
[11]	CALDERON M A,ALVES B,JACOBSON M,et al.Allergen injection immunotherapy for seasonal allergic rhinitis[J].Cochrane Database Syst Rev,2007,24:CD001936.
[12]	程雷,李华斌.世界变态反应组织舌下免疫治疗意见书(2009)解读[J].中华耳鼻咽喉头颈外科杂志,2011,46(1):80-83.
[13]	EIFAN A O,AKKOC T,YILDIZ A,et al.Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite:an open randomized controlled trial[J].Clin Exp Allergy,2010,40:922-932.
[14]	朱亮,朱鲁平,陈若希,等.皮下免疫和舌下免疫治疗尘螨变应性鼻炎的疗效分析[J].中华耳鼻咽喉头颈外科杂志,2011,46(12):986-991.
[15]	AASBJERG K,DALHOFF K P,BACKER V,et al.Adverse events during immunotherapy against grass pollen-induced allergic rhinitis-differences between subcutaneous and sublingual treatment[J].Basic Clin Pharmacol Toxicol,2015,117:73-84.
[16]	李添应,陈德华,林志斌.舌下含服粉尘螨滴剂治疗变应性鼻炎的疗效观察[J].中华耳鼻咽喉头颈外科杂志,2011,46(10):859-862.
[17]	温赤君,朱明风,任文美,等.舌下粉尘螨滴剂治疗儿童支气管哮喘伴变应性鼻炎的有效性和安全性[J].中华耳鼻咽喉头颈外科杂志,2011,46(5):393-396.
[18]	BERNSTEIN D I,WANNER M,BORISH L,et al.Twelve-year survey of fatal reactions to allergen injections and skin testing:1990-2001[J].J Allergy Clin Immun,2004,113:1129-1136.
[19]	王洪田,尤少华.变应性鼻炎的规范诊断与治疗[J].武警医学,2013,11(7):553-556.